Erbitux cleared for first-line colorectal cancer use in Japan
This article was originally published in Scrip
Lilly (ImClone Systems)/Merck KGaA/Bristol-Myers Squibb's Erbitux (cetuximab) has been approved in Japan for the first-line treatment of selected metastatic colorectal cancer patients.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.